Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267418 | 0.81 | TSHR (0.53) | TSHRLMNAF2TDP1KMT2A | |
| SCHEMBL11378444 | 0.81 | TSHR (0.48) | TSHRLMNAF2TDP1KMT2A | |
| SCHEMBL9668519 | 0.80 | POLB (0.50) | TSHRLMNAF2TDP1KMT2A | |
| SCHEMBL9801767 | 0.80 | HDAC3 (0.51) | TSHRLMNAF2TDP1KMT2A | |
| SCHEMBL25418243 | 0.79 | LTA4H (0.44) | LMNAKMT2AMAPK1BCHE | |
| SCHEMBL31432434 | 0.79 | KMT2A (0.53) | TSHRLMNAF2TDP1KMT2A | |
| SCHEMBL28554560 | 0.77 | TDP1 (0.58) | TSHRLMNATDP1KMT2AALDH1A1 | |
| SCHEMBL1902999 | 0.77 | MAPK1 (0.55) | TSHRLMNAKMT2AALDH1A1MAPK1 | |
| SCHEMBL11260963 | 0.76 | TSHR (0.56) | TSHRLMNAF2TDP1KMT2A | |
| SCHEMBL5579337 | 0.76 | BCHE (0.45) | TSHRLMNAF2TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222548-A1 | METHOD FOR PRODUCING CONDENSATION PRODUCTS FROM N-SUBSTITUTED GLYCINE DERIVATIVES(PEPTOIDS) BY SEQUENTIAL UGI-MULTICOMPONENT REACTIONS | WESSJOHANN LUDGER | 2010-09-02 | — | — | US | disclosed |
| EP-2051992-B1 | METHOD FOR PRODUCING CONDENSATION PRODUCTS FROM N-SUBSTITUTED GLYCINE DERIVATIVES (PEPTOIDS) BY SEQUENTIAL UGI-MULTICOMPONENT REACTIONS | LEIBNIZ INST FUER PFLANZENBIOC (DE) | 2010-08-04 | — | — | EP | disclosed |
| EP-2051992-A1 | METHOD FOR PRODUCING CONDENSATION PRODUCTS FROM N-SUBSTITUTED GLYCINE DERIVATIVES (PEPTOIDS) BY SEQUENTIAL UGI-MULTICOMPONENT REACTIONS | Institut für Pflanzenbiochemie-IPB (DE) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008022800-A1 | METHOD FOR PRODUCING CONDENSATION PRODUCTS FROM N-SUBSTITUTED GLYCINE DERIVATIVES (PEPTOIDS) BY SEQUENTIAL UGI-MULTICOMPONENT REACTIONS | LEIBNIZ-INSTITUT FÜR PFLANZENBIOCHEMIE (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222548-A1 | METHOD FOR PRODUCING CONDENSATION PRODUCTS FROM N-SUBSTITUTED GLYCINE DERIVATIVES(PEPTOIDS) BY SEQUENTIAL UGI-MULTICOMPONENT REACTIONS | QPCT, GMPS, GMNN | TSHR 4700/4885LMNA 199/4885F2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.